Article - 16/06/2008 Apogenix raises 27.5 million euros Apogenix GmbH a biopharmaceutical company announced the closing of its second financing round. dievini Hopp BioTech holding GmbH Co. KG the investment company of SAP co-founder Dietmar Hopp was the main investor.https://www.gesundheitsindustrie-bw.de/en/article/news/apogenix-raises-27-5-million-euros
Article - 05/11/2009 CLAIR provides new insights The human eye is a fascinating organ as well as model for the specialists at Stockach-based Sensovation AG. Their complex optical detection systems are based on CCD and CMOS technologies. However a high-tech sensor is able to recognise much more than many eyes put together. https://www.gesundheitsindustrie-bw.de/en/article/news/clair-provides-new-insights
Personalised Medicine - 04/05/2017 Big data make therapy work better An international team of researchers has shown for acute myeloid leukaemia (AML) that cancer therapy can be personalised using big data. The authors of the study “believe this paper is a step towards validation of genetic techniques as a route to personalised medicine”. https://www.gesundheitsindustrie-bw.de/en/article/news/mit-big-data-genauer-therapieren
Press release - 01/12/2009 Stefan Wiemann elected new spokesman of the German Genome Research Network Associate Professor (PD) Dr. Stefan Wiemann of the German Cancer Research Centre (Deutsches Krebsforschungszentrum, DKFZ) has been elected spokesman of the Project Committee of the National Genome Research Network. This funding programme supports projects in medical genome research aimed at fighting relevant widespread diseases. https://www.gesundheitsindustrie-bw.de/en/article/press-release/stefan-wiemann-elected-new-spokesman-of-the-german-genome-research-network
Press release - 04/02/2010 Signalling pathway in cancer cells needs acid: new targets for tailor-made therapies? The Wnt signalling pathway plays an important role in embryonic development, in stem cells and also in diseases such as cancer. Some of the individual steps of this signalling pathway are not yet known in detail including in particular the mechanism by which the Wnt protein activates the Wnt receptor during binding. Scientists from the German Cancer Research Centre (Deutsches Krebsforschungszentrum, DKFZ) have now made a substantial contribution…https://www.gesundheitsindustrie-bw.de/en/article/press-release/signalling-pathway-in-cancer-cells-needs-acid-new-targets-for-tailor-made-therapies
Article - 12/12/2011 siRNA in cancer therapy : Tübingen researchers awarded prize by the German Society of Thoracic Surgery Short ribonucleic acid molecules only 21 nucleotides long are providing new impulses for lung cancer treatment. A team of doctors and biologists from the University of Tübingen have been awarded a prize by the German Society of Thoracic Surgery for their research on siRNA.https://www.gesundheitsindustrie-bw.de/en/article/news/sirna-in-cancer-therapy-tuebingen-researchers-awarded-prize-by-the-german-society-of-thoracic-surger
Article - 30/04/2011 The DKFZ-ZMBH Alliance The strategic alliance between the cell and tumour biology research priority at the German Cancer Research Center and the Center for Molecular Biology at Universität Heidelberg has led to the development of one of the largest centres of basic biomedical research in Germany. The top international profile of this interdisciplinary institution located at the interface between molecular and cellular biology tumour biology and biomedicine is reflected…https://www.gesundheitsindustrie-bw.de/en/article/news/the-dkfz-zmbh-alliance
Article - 16/04/2008 Roland Schuele - "Research cannot be predicted" Professor Roland Schuele from the University Womens Hospital in Freiburg originally studied biochemistry. Nowadays Schuele is researching the development of prostate cancer. During his scientific career he has learnt that research cannot be steered in a particular direction. It develops and we follow it said Schuele who has been able to gain astonishing insights into the molecular processes in tumour cells.https://www.gesundheitsindustrie-bw.de/en/article/news/roland-schuele-research-cannot-be-predicted
Press release - 31/03/2009 Cancer researcher from Heidelberg awarded the Dr. Hella Bühler Prize Dr. Ronald Koschny assistant doctor in the Department of Gastroenterology at the University Hospital in Heidelberg was awarded the Dr. Hella Bühler Prize. Koschny received the prize which comes with a cheque for 100000 euros for his groundbreaking work on finding new therapies in particular therapies for the treatment of pancreatic cancer.https://www.gesundheitsindustrie-bw.de/en/article/press-release/cancer-researcher-from-heidelberg-awarded-the-dr-hella-buehler-prize
Dossier - 13/04/2015 Boosting the immune system can improve cancer prevention and treatment The activation of the body’s immune system to fight cancer is not only a promising therapeutic concept, but is already used in medical practice. The first immunotherapies have been approved and many more are either in the experimental stages or already undergoing clinical testing. Vaccines to prevent certain types of cancer are already being used successfully around the world.https://www.gesundheitsindustrie-bw.de/en/article/dossier/boosting-the-immune-system-can-improve-cancer-prevention-and-treatment
Article - 14/03/2011 Synthesising proteins from non-natural building blocks? Dr. Birgit Wiltschi from the University of Freiburg has been awarded funding from the Baden-Württemberg Ministry of Science Research and the Arts under the Biotechnology and Medical Technology Idea Competition for a highly ambitious project she wants to learn how proteins can be modified using non-natural building blocks that will enable the engineered proteins to specifically target receptors on cancer cells amongst other things.https://www.gesundheitsindustrie-bw.de/en/article/news/synthesising-proteins-from-non-natural-building-blocks
Article - 07/11/2011 Daniel Gebhard – a new chapter in the mitochondrial theory of aging It has been known for quite some time that skin aging and skin cancer are connected with UV radiation. It is believed that mutations in the mitochondrial DNA are major contributors to aging and cancer, which is why in-depth knowledge about the repair mechanisms of skin cells is essential. Daniel Gebhard, doctoral student at Albstadt-Sigmaringen University, is investigating the repair capacity of mtDNA in different human skin cell types. He is…https://www.gesundheitsindustrie-bw.de/en/article/news/daniel-gebhard-a-new-chapter-in-the-mitochondrial-theory-of-aging
Article - 09/01/2012 Nutritional medicine: Can certain foods help treat cancer? Researchers at the Centre for Nutritional Medicine (ZEM), a joint institution of the Universities of Hohenheim and Tübingen, are investigating whether and to what extent certain food components can support the treatment of cancer and are hoping to derive scientifically founded dietary recommendations from their findings.https://www.gesundheitsindustrie-bw.de/en/article/news/nutritional-medicine-can-certain-foods-help-treat-cancer
Press release - 23/07/2009 Mannheim Medical Centre – leading cancer laboratory and clinical research centre Mannheim is the only medical centre in Germany to fulfil the criteria of an affiliated centre of EORTC. According to a recent EORTC report Mannheim is the only German centre that has fulfilled the organisations high quality criteria over the last three years. https://www.gesundheitsindustrie-bw.de/en/article/press-release/mannheim-medical-centre-leading-cancer-laboratory-and-clinical-research-centre
Press release - 19/11/2010 Affimed enrols first patients in Phase I Hodgkin’s lymphoma study The Heidelberg-based biotech company Affimed Therapeutics AG announced on 15th November 2010 that the first Hodgkin’s lymphoma patients have been treated with the AFM13 TandAb® antibody in a Phase I clinical study. Thus, the “first-in-man” tetravalent, bispecific antibody based on the company’s proprietary RECRUIT-TandAb® antibody technology has entered the clinic.https://www.gesundheitsindustrie-bw.de/en/article/press-release/affimed-enrols-first-patients-in-phase-i-hodgkin-s-lymphoma-study
Article - 25/08/2008 Rare kidney tumour leads the way to a new cancer therapy Renal cell carcinoma is a rare disease. In addition, the disease is difficult to treat, and the majority of pharmaceutical companies find the development of new drugs for its treatment too financially risky. Their argument: the market is too small to make up for the high development costs. The Tübingen biotech company immatics was courageous enough to do so and will now be rewarded. The immatics scientists have developed a therapy that not only…https://www.gesundheitsindustrie-bw.de/en/article/news/rare-kidney-tumour-leads-the-way-to-a-new-cancer-therapy
Article - 27/07/2015 Looking for the Achilles’ heel of the tumour Although medicines that inhibit the growth of cancer cells are available, the prognosis for patients with solid tumours is generally still rather poor. The reason for this is that tumour cells develop resistance to therapy during treatment, and the tumour can continue to grow. However, tumours are vulnerable – if only more robust medicines were available. Prof. Dr. Lars Zender, senior physician and head of the Division of Translational…https://www.gesundheitsindustrie-bw.de/en/article/news/looking-for-the-achilles-heel-of-the-tumour
Press release - 18/11/2008 Oxygen radicals alter immune cells Researchers from Heidelberg have discovered that certain oxygen compounds are produced in greater quantities in the body due to cancer or inflammation and that this leads to the alteration of a protein that controls the flexibility and adaptability of certain immune cells.https://www.gesundheitsindustrie-bw.de/en/article/press-release/oxygen-radicals-alter-immune-cells
Dossier - 20/12/2010 Environmental toxins: effect and origin Environmental toxins, also referred to as xenobiotics, are chemicals that do not occur in biological substance cycles; they are difficult to degrade and often have a toxic effect. Xenobiotic substances are becoming an increasing problem because we are constantly exposed to them and because they slowly but surely poison us. The World Health Organisation (WHO) sees xenobiotic substances as factors that contribute, along with other factors, to the…https://www.gesundheitsindustrie-bw.de/en/article/dossier/environmental-toxins-effect-and-origin
Press release - 03/11/2015 CureVac raises $110 Million in a private placement CureVac, a clinical-stage biopharmaceutical company pioneering the field of mRNA-based technology, today announces that it has raised about $110 million (€100 million) to enable accelerated expansion of its industry-leading messenger RNA (mRNA) development platform and clinical-stage pipeline. CureVac also announces the change of its corporate legal form to a joint stock company, Aktiengesellschaft (AG).https://www.gesundheitsindustrie-bw.de/en/article/press-release/curevac-raises-110-million-in-a-private-placement
Article - 22/10/2019 Using CAR T cells for treating cancer After successes in the treatment of advanced blood cancers, CAR T-cell immunotherapy has become a major beacon of hope in oncology. The first therapies have received regulatory approval. Despite their success, these immunotherapies can have serious side effects. The company AVA Lifescience develops antibodies with high tumour specificity to use as the basis for effective precision-guided CAR T-cell therapies that are better tolerated by patients.https://www.gesundheitsindustrie-bw.de/en/article/news/using-car-t-cells-for-treating-cancer
Article - 15/11/2008 Heidelberg students win at the iGEM competition The Heidelberg team of 16 students has achieved an outstanding result at the renowned iGEM competition organised by the MIT in Boston. The team won the largest number of prizes with its project Ecolicence to Kill including a gold medal for their scientific work.https://www.gesundheitsindustrie-bw.de/en/article/press-release/heidelberg-students-win-at-the-igem-competition
Article - 21/08/2009 Patenting and clinical trials go hand in hand Back when he was doing his degree thesis at the German Cancer Research Centre in Heidelberg the immunologist Prof. Peter Öhlschläger who now works at the University of Constance laid down the basic principles for developing an artificial gene for the treatment of cervical cancer. Prof. Öhlschläger is currently in the process of filing a patent for DNA vaccines for HPV. In the following interview the scientist says that the greatest challenges are…https://www.gesundheitsindustrie-bw.de/en/article/news/patenting-and-clinical-trials-go-hand-in-hand
Press release - 10/12/2012 Sex hormone induces elongation of stem cell telomeres The telomere ends of chromosomes become shorter with any cell division round. This is why the lifespan of most cells is limited. One of several exceptions to this rule is the haematopoietic stem cells of the bone marrow. The enzyme telomerase enables them compensate telomere attrition. However defective telomerase function can cause bone marrow failure disorders such as aplastic anaemia amongst others. Prof. Dr. Uwe Martens from the SLK Hospital…https://www.gesundheitsindustrie-bw.de/en/article/press-release/sex-hormone-induces-elongation-of-stem-cell-telomeres
Article - 08/04/2013 The first major cell migration It is of crucial importance that cells stick tightly together where their function requires them to do so for example in organs such as the heart and the liver to name but two examples. However it is equally crucial that cells start to migrate at some stage during embryonic development in order to form such organs. Prof. Dr. Wolfgang Driever from the Institute of Biology I at the University of Freiburg and his team have elucidated the molecular…https://www.gesundheitsindustrie-bw.de/en/article/news/the-first-major-cell-migration